Drilon A - Search Results

1

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.

Friedlaender A, Drilon A, Weiss GJ, Banna GL, Addeo A. Friedlaender A, et al. Among authors: drilon a. Cancer Treat Rev. 2020 Apr;85:101978. doi: 10.1016/j.ctrv.2020.101978. Epub 2020 Feb 7. Cancer Treat Rev. 2020. PMID: 32062493 Free PMC article. Review.

2

Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy.

Drilon A, Rekhtman N, Ladanyi M, Paik P. Drilon A, et al. Lancet Oncol. 2012 Oct;13(10):e418-26. doi: 10.1016/S1470-2045(12)70291-7. Lancet Oncol. 2012. PMID: 23026827 Review.

3

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, Ross J, Miller V, Ginsberg M, Zakowski MF, Kris MG, Ladanyi M, Rizvi N. Drilon A, et al. Cancer Discov. 2013 Jun;3(6):630-5. doi: 10.1158/2159-8290.CD-13-0035. Epub 2013 Mar 26. Cancer Discov. 2013. PMID: 23533264 Free PMC article. Clinical Trial.

4

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.

Paik PK, Drilon A, Fan PD, Yu H, Rekhtman N, Ginsberg MS, Borsu L, Schultz N, Berger MF, Rudin CM, Ladanyi M. Paik PK, et al. Among authors: drilon a. Cancer Discov. 2015 Aug;5(8):842-9. doi: 10.1158/2159-8290.CD-14-1467. Epub 2015 May 13. Cancer Discov. 2015. PMID: 25971939 Free PMC article.

5

KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.

Naidoo J, Drilon A. Naidoo J, et al. Among authors: drilon a. Adv Exp Med Biol. 2016;893:155-178. doi: 10.1007/978-3-319-24223-1_8. Adv Exp Med Biol. 2016. PMID: 26667343 Review.

6

Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.

Drilon A, Eaton AA, Schindler K, Gounder MM, Spriggs DR, Harris P, Ivy SP, Iasonos A, Lacouture ME, Hyman DM. Drilon A, et al. Cancer. 2016 Apr 15;122(8):1228-37. doi: 10.1002/cncr.29918. Epub 2016 Feb 24. Cancer. 2016. PMID: 26916138 Free PMC article.

7

MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.

Drilon A. Drilon A. Clin Cancer Res. 2016 Jun 15;22(12):2832-4. doi: 10.1158/1078-0432.CCR-16-0229. Epub 2016 Mar 23. Clin Cancer Res. 2016. PMID: 27009743 Free PMC article.

8

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ. Jordan EJ, et al. Among authors: drilon a. Cancer Discov. 2017 Jun;7(6):596-609. doi: 10.1158/2159-8290.CD-16-1337. Epub 2017 Mar 23. Cancer Discov. 2017. PMID: 28336552 Free PMC article.

9

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.

Drilon A, Hu ZI, Lai GGY, Tan DSW. Drilon A, et al. Nat Rev Clin Oncol. 2018 Mar;15(3):151-167. doi: 10.1038/nrclinonc.2017.175. Epub 2017 Nov 14. Nat Rev Clin Oncol. 2018. PMID: 29134959 Free PMC article. Review.

10

Tumor-Agnostic Drug Development.

Offin M, Liu D, Drilon A. Offin M, et al. Among authors: drilon a. Am Soc Clin Oncol Educ Book. 2018 May 23;38:184-187. doi: 10.1200/EDBK_200831. Am Soc Clin Oncol Educ Book. 2018. PMID: 30231313 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

249 results

Search Page